Published in Acta Biochim Pol on March 16, 2010
Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol (2012) 2.99
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
Corticotropin-releasing factor signaling and visceral response to stress. Exp Biol Med (Maywood) (2010) 1.18
Tobacco addiction and the dysregulation of brain stress systems. Neurosci Biobehav Rev (2012) 1.09
Structural basis for hormone recognition by the Human CRFR2{alpha} G protein-coupled receptor. J Biol Chem (2010) 1.08
Role of Corticotropin-releasing Factor Signaling in Stress-related Alterations of Colonic Motility and Hyperalgesia. J Neurogastroenterol Motil (2015) 1.01
Role of TRPM in melanocytes and melanoma. Exp Dermatol (2012) 0.98
CRF and urocortin peptides as modulators of energy balance and feeding behavior during stress. Front Neurosci (2014) 0.89
Corticotropin-releasing hormone receptor 1 gene variants in irritable bowel syndrome. PLoS One (2012) 0.88
Alternative Splicing of the Pituitary Adenylate Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of Brain Activity. Front Endocrinol (Lausanne) (2013) 0.82
Urocortin protects chondrocytes from NO-induced apoptosis: a future therapy for osteoarthritis? Cell Death Dis (2013) 0.81
Consequences of splice variation on Secretin family G protein-coupled receptor function. Br J Pharmacol (2012) 0.81
Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli. PLoS One (2014) 0.81
Activation of Type 1 CRH receptor isoforms induces serotonin release from human carcinoid BON-1N cells: an enterochromaffin cell model. Endocrinology (2010) 0.81
Neuroendocrinology of the skin: An overview and selective analysis. Dermatoendocrinol (2011) 0.81
Corticotrophin-releasing factor, related peptides, and receptors in the normal and inflamed gastrointestinal tract. Front Neurosci (2011) 0.81
Urocortins and CRF type 2 receptor isoforms expression in the rat stomach are regulated by endotoxin: role in the modulation of delayed gastric emptying. Am J Physiol Gastrointest Liver Physiol (2012) 0.79
The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats. PLoS One (2013) 0.79
Evidence for the role of corticotropin-releasing factor in major depressive disorder. Neurosci Biobehav Rev (2015) 0.77
Corticotropin-releasing Hormone and Its Biological Diversity toward Angiogenesis. Intest Res (2014) 0.77
Multi-facets of Corticotropin-releasing Factor in Modulating Inflammation and Angiogenesis. J Neurogastroenterol Motil (2015) 0.77
The cochlear CRF signaling systems and their mechanisms of action in modulating cochlear sensitivity and protection against trauma. Mol Neurobiol (2011) 0.76
Don't stress about CRF: assessing the translational failures of CRF1antagonists. Psychopharmacology (Berl) (2017) 0.76
The CRF System as a Therapeutic Target for Neuropsychiatric Disorders. Trends Pharmacol Sci (2016) 0.75
Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest (2017) 0.75
Activation of Brain Somatostatin Signaling Suppresses CRF Receptor-Mediated Stress Response. Front Neurosci (2017) 0.75
Anatomical Organization of Urocortin 3-Synthesizing Neurons and Immunoreactive Terminals in the Central Nervous System of Non-Human Primates [Sapajus spp.]. Front Neuroanat (2017) 0.75
I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science (1988) 16.40
Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci U S A (2002) 10.28
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA (1992) 6.96
Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov (2008) 6.18
The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med (1995) 6.17
Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev (2004) 5.89
CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol (2004) 5.21
Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol (2000) 4.17
Endocrinology of the stress response. Annu Rev Physiol (2005) 3.74
Neuroendocrinology of the skin. Endocr Rev (2000) 3.34
Early nonsense: mRNA decay solves a translational problem. Nat Rev Mol Cell Biol (2006) 3.11
Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev (1991) 3.07
Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev (2000) 2.98
Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A (2001) 2.87
Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev (1999) 2.77
Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A (1993) 2.70
Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron (1993) 2.10
The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev (2006) 2.08
Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci (1999) 2.04
G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol Rev (2007) 1.98
Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets (2006) 1.97
GPCR monomers and oligomers: it takes all kinds. Trends Neurosci (2008) 1.97
Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A (1981) 1.78
Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry (2007) 1.78
Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J Clin Invest (2007) 1.77
Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J (2001) 1.74
Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocr Rev (1988) 1.73
Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol (2006) 1.72
Neuroimmunology of stress: skin takes center stage. J Invest Dermatol (2006) 1.72
Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science (1991) 1.70
Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol (2003) 1.66
Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J (2001) 1.59
In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology (1996) 1.57
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem (2002) 1.53
Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci (2004) 1.50
Alternative splicing of the G protein-coupled receptor superfamily in human airway smooth muscle diversifies the complement of receptors. Proc Natl Acad Sci U S A (2008) 1.47
Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab (2002) 1.46
Differential expression of a cutaneous corticotropin-releasing hormone system. Endocrinology (2003) 1.46
Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A (1995) 1.45
Corticotropin releasing hormone and the skin. Front Biosci (2006) 1.45
Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett (2006) 1.45
The regulatory mechanisms of export trafficking of G protein-coupled receptors. Cell Signal (2005) 1.44
Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci U S A (1995) 1.42
Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol (2006) 1.41
ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. J Clin Endocrinol Metab (1996) 1.41
CRH functions as a growth factor/cytokine in the skin. J Cell Physiol (2006) 1.38
Regulation of involucrin gene expression. J Invest Dermatol (2004) 1.36
Substances that can change alternative splice-site selection. Biochem Soc Trans (2008) 1.34
The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology (1999) 1.32
Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res (1999) 1.29
Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides (2009) 1.24
Molecular and functional characterization of novel CRFR1 isoforms from the skin. Eur J Biochem (2004) 1.22
Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci U S A (2002) 1.22
A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol (1999) 1.21
Skin as an endocrine organ: implications for its function. Drug Discov Today Dis Mech (2008) 1.19
Differential regulation of corticotropin releasing factor 1alpha receptor endocytosis and trafficking by beta-arrestins and Rab GTPases. J Neurochem (2006) 1.19
Role of corticotropin-releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors. Endocrinology (2003) 1.19
Cutaneous expression of CRH and CRH-R. Is there a "skin stress response system?". Ann N Y Acad Sci (1999) 1.18
Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor. J Biol Chem (2001) 1.17
Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. Ann N Y Acad Sci (2006) 1.17
Characterization of a ultraviolet B-induced corticotropin-releasing hormone-proopiomelanocortin system in human melanocytes. Mol Endocrinol (2006) 1.16
Corticotropin-releasing hormone induces keratinocyte differentiation in the adult human epidermis. J Cell Physiol (2005) 1.14
Molecular cascades in UV-induced melanogenesis: a central role for melanotropins? Pigment Cell Res (1992) 1.14
Potential mechanism of skin response to stress. Int J Dermatol (1996) 1.13
Neuroendocrine activity of the melanocyte. Exp Dermatol (2009) 1.12
The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res (2000) 1.11
The CRHR1 gene: a marker for suicidality in depressed males exposed to low stress. Genes Brain Behav (2007) 1.10
Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes. J Endocrinol (2004) 1.10
Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor. Endocrinology (1995) 1.10
The alternatively spliced deltae13 transcript of the rabbit calcitonin receptor dimerizes with the C1a isoform and inhibits its surface expression. J Biol Chem (2003) 1.09
"Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol (2006) 1.08
Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes. Mol Cancer Ther (2008) 1.08
A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci U S A (2005) 1.08
From the brain-skin connection: the neuroendocrine-immune misalliance of stress and itch. Neuroimmunomodulation (2007) 1.07
Pleiotropic effects of corticotropin releasing hormone on normal human skin keratinocytes. In Vitro Cell Dev Biol Anim (2001) 1.07
Characterization of corticotropin-releasing hormone (CRH) in human skin. J Clin Endocrinol Metab (1998) 1.06
Ultraviolet B stimulates production of corticotropin releasing factor (CRF) by human melanocytes. FEBS Lett (1996) 1.06
A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity. J Biol Chem (2003) 1.06
Corticotropin releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes. In Vitro Cell Dev Biol Anim (2000) 1.04
On the potential role of proopiomelanocortin in skin physiology and pathology. Mol Cell Endocrinol (1993) 1.04
Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor. Biochem Soc Trans (2007) 1.03
On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders. Br J Dermatol (2009) 1.02
Dimerization of corticotropin-releasing factor receptor type 1 is not coupled to ligand binding. J Recept Signal Transduct Res (2005) 1.02
Interacting effects of CRHR1 gene and stressful life events on drinking initiation and progression among 19-year-olds. Int J Neuropsychopharmacol (2009) 1.02
Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. FEBS Lett (1995) 1.02
Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist. J Med Chem (2007) 1.01
HPA-axis activity in alcoholism: examples for a gene-environment interaction. Addict Biol (2007) 1.01
CRF1 receptor splicing in epidermal keratinocytes: potential biological role and environmental regulations. J Cell Physiol (2009) 1.00
Pharmacogenetics of asthma. Curr Opin Pulm Med (2009) 0.99
Expression of molecular equivalent of hypothalamic-pituitary-adrenal axis in adult retinal pigment epithelium. J Endocrinol (2007) 0.98
Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res (2001) 0.98
Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. Mol Pharmacol (2009) 0.97
Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells. FEBS Lett (1998) 0.97
Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. Mol Endocrinol (2000) 0.97
The onset of labor alters corticotropin-releasing hormone type 1 receptor variant expression in human myometrium: putative role of interleukin-1beta. Endocrinology (2007) 0.96
Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol (2008) 0.96
CRH inhibits NF-kappa B signaling in human melanocytes. Peptides (2006) 0.96
Liquid chromatography-mass spectrometry detection of corticotropin-releasing hormone and proopiomelanocortin-derived peptides in human skin. J Clin Endocrinol Metab (2000) 0.96
20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol (2008) 1.91
20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes. PLoS One (2009) 1.65
Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum Pathol (2013) 1.50
Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol (2012) 1.47
20,23-dihydroxyvitamin D3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes. J Cell Physiol (2010) 1.44
Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol (2011) 1.38
Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy. Int J Cancer (2008) 1.33
Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids (2008) 1.24
Cytochromes p450 and skin cancer: role of local endocrine pathways. Anticancer Agents Med Chem (2014) 1.20
Corticotropin-releasing hormone induces keratinocyte differentiation in the adult human epidermis. J Cell Physiol (2005) 1.14
Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes. J Endocrinol (2004) 1.10
Expression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression. Hum Pathol (2012) 1.09
Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci (2008) 1.09
Vitamin D analogs 17,20S(OH)2pD and 17,20R(OH)2pD are noncalcemic and exhibit antifibrotic activity. J Invest Dermatol (2011) 1.08
The role of melanin pigment in melanoma. Exp Dermatol (2015) 1.03
Metabolism of melatonin and biological activity of intermediates of melatoninergic pathway in human skin cells. FASEB J (2013) 1.02
Synthesis and photochemical transformation of 3β,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity. Steroids (2010) 1.01
CRF1 receptor splicing in epidermal keratinocytes: potential biological role and environmental regulations. J Cell Physiol (2009) 1.00
Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength. Mol Cell Endocrinol (2012) 0.99
Expression of molecular equivalent of hypothalamic-pituitary-adrenal axis in adult retinal pigment epithelium. J Endocrinol (2007) 0.98
Genetic variation of the cutaneous HPA axis: an analysis of UVB-induced differential responses. Gene (2013) 0.98
Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Res (2007) 0.97
CRH inhibits NF-kappa B signaling in human melanocytes. Peptides (2006) 0.96
Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity. Anticancer Res (2014) 0.95
CRH mediates inflammation induced by lipopolysaccharide in human adult epidermal keratinocytes. J Invest Dermatol (2006) 0.94
New vitamin D analogs as potential therapeutics in melanoma. Expert Rev Anticancer Ther (2012) 0.94
Design, synthesis, and biological action of 20R-hydroxyvitamin D3. J Med Chem (2012) 0.93
Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1. Drug Metab Dispos (2013) 0.92
Corticotropin-releasing hormone inhibits nuclear factor-kappaB pathway in human HaCaT keratinocytes. J Invest Dermatol (2003) 0.92
The role of constitutively activated STAT3 in B16 melanoma cells. Int J Interferon Cytokine Mediat Res (2010) 0.91
Metabolism of cholesterol, vitamin D3 and 20-hydroxyvitamin D3 incorporated into phospholipid vesicles by human CYP27A1. J Steroid Biochem Mol Biol (2011) 0.91
Human cytochrome P450scc (CYP11A1) catalyzes epoxide formation with ergosterol. Drug Metab Dispos (2011) 0.90
Synergistic activation of steroidogenic acute regulatory protein expression and steroid biosynthesis by retinoids: involvement of cAMP/PKA signaling. Endocrinology (2013) 0.88
Human female hair follicles are a direct, nonclassical target for thyroid-stimulating hormone. J Invest Dermatol (2008) 0.85
High-resolution magic angle spinning nuclear magnetic resonance analysis of metabolic changes in melanoma cells after induction of melanogenesis. Anal Biochem (2008) 0.84
The melatonin-producing system is fully functional in retinal pigment epithelium (ARPE-19). Mol Cell Endocrinol (2009) 0.83
Neuroendocrinology of the skin: An overview and selective analysis. Dermatoendocrinol (2011) 0.81
Transplantable melanomas in gerbils (Meriones unguiculatus). II: melanogenesis. Exp Dermatol (2003) 0.80
Commentary on the practical guide for the study of sebaceous glands. Exp Dermatol (2013) 0.78
N1-Acetyl-5-Methoxykynuramine (AMK) is produced in the human epidermis and shows antiproliferative effects. Endocrinology (2015) 0.77
Effects of in utero exposure of C57BL/6J mice to 2,3,7,8-tetrachlorodibenzo-p-dioxin on epidermal permeability barrier development and function. Environ Health Perspect (2014) 0.77
Is Mc1r an important regulator of non-pigmentary responses to UV radiation? Exp Dermatol (2013) 0.77
Targeting ALDH1A1 to treat pigmentary disorders. Exp Dermatol (2013) 0.75